Menu
Not yet recruiting NCT07545525

HPV Testing as a Prevention of Cervical Dysplasia and Cancer Before Planned Subtotal Hysterectomy

Observational Cervical Cancer Screening Human Papilloma Virus (HPV)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Cervical Cancer Screening, Human Papilloma Virus (HPV). Basic parameters: from 18 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

HPV Testing as a Prevention of Cervical Dysplasia and Cervical Cancer Before Planned Subtotal Hysterectomy

Overview

Patients indicated for subtotal hysterectomy will be tested for High risk HPV and if the result is positive will undergo expert colposcopy and conisation if not indicated otherwise at the time of subtotal hysterectomy

Primary outcome measures

  • Benefit of addition of HPV DNA testing before subtotal hysterectomy [Time frame: 3 years]

Eligibility criteria

Inclusion criteria

  • age over 18
  • indication for subtotal hysterectomy
  • consent to provide conisation in case the HPV test result is positive

Exclusion criteria

  • negative HPV test in the last 3 years

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07545525 · 032026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗